United Kingdom Following fears of variant Creutzfeldt-Jakob disease (vCJD) being spread through the blood supply, the British government began to import plasma (to meet the need for commercially manufactured fractionated plasma medicines) and (through devolved Blood Services) imported plasma from Europe (to meet the needs for plasma blood components for certain patient groups) . In 2002, the British government purchased Life Resources Incorporated  to import plasma for medicines made from fractionated plasma . The company became Plasma Resources UK (PRUK) which owned Bio Products Laboratory. In 2013, the British government sold an 80\% stake in PRUK to American hedge fund Bain Capital, in a deal estimated to be worth £ 230 million. The sale was met with criticism in the UK  .
United Kingdom Following fears of variant Creutzfeldt-Jakob disease (vCJD) being spread through the blood supply, the British government began to phase out blood plasma from U.K. donors and by the end of 1999 had imported all blood products made with plasma from the United States . In 2002, the British government purchased Life Resources Incorporated , an American blood supply company, to import plasma . The company became Plasma Resources UK (PRUK) which owned Bio Products Laboratory. In 2013, the British government sold an 80\% stake in PRUK to American hedge fund Bain Capital, in a deal estimated to be worth £ 200 million. The sale was met with criticism in the UK . In 2009, the U.K. stopped importing plasma from the United States, as it was no longer a viable option due to regulatory and jurisdictional challenges .
R
import plasma (to meet the need for commercially manufactured fractionated plasma medicines) and (through devolved Blood Services) imported plasma from Europe (to meet the needs for plasma blood components for certain patient groups)
phase out blood plasma from U.K. donors and by the end of 1999 had imported all blood products made with plasma from the United States
A
, an American blood supply company,
D
for medicines made from fractionated plasma
R
230
200
A
. In 2009, the U.K. stopped importing plasma from the United States, as it was no longer a viable option due to regulatory and jurisdictional challenges